Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2012 Q2- Text added to 2012 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
abbreviated, adding, AEs, age, baseline, CI, cough, death, Department, diarrhea, discontinuation, ensuing, exceeded, ezetimibe, fatigue, fight, Hazard, headache, HeFH, HR, hypercholesterolemic, hypothetical, infection, Inspector, Interval, median, MENDEL, mg, movement, myalgia, nausea, notable, older, parathyroidectomy, pathway, pioneer, placebo, predictor, quickly, Ratio, reaction, reserve, respiratory, rheumatoid, romosozumab, RUTHERFORD, Sequentially, showed, titled, tolerate, tract, transplant, turn, upper, ustekinumab, voluntarily, Week
Valuein 2012 Q2 filing- Value in 2012 Q3 filing
Original filings
Filing view